Creatine Kinase BB Levels in Breast Cancer and Patient Survival
Author Information
Author(s): N Zarghami, M Giai, H Yu, R Roagna, R Ponzone, D Katsaros, P Sismondi, E P Diamandis
Primary Institution: Mount Sinai Hospital and University of Toronto
Hypothesis
Is there an association between creatine kinase BB levels in breast cancer tumors and patient survival?
Conclusion
High levels of creatine kinase BB in breast cancer tumors are associated with a higher risk of death, particularly in patients with estrogen receptor-negative cancer.
Supporting Evidence
- High CK-BB levels were more frequent in younger patients and those who qualified for chemotherapy.
- Patients with high CK-BB levels had a statistically significant higher risk of death in multivariate analysis.
- CK-BB levels did not significantly associate with clinical stage, histological grade, or tumor size.
Takeaway
This study found that patients with higher levels of a specific enzyme in their breast cancer tumors might not live as long, especially if their cancer doesn't respond to estrogen.
Methodology
The study measured creatine kinase BB levels in tumor cytosols from 172 breast cancer patients and analyzed associations with clinical variables and survival outcomes.
Potential Biases
Potential biases may arise from the selection of patients and the retrospective nature of the study.
Limitations
The study's findings may not be generalizable due to the specific patient population and the limited number of patients with certain characteristics.
Participant Demographics
Patients aged between 25 and 91 years, with a median age of 56 years; 70% had ductal carcinomas.
Statistical Information
P-Value
0.03
Confidence Interval
0.76-2.59
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website